Baird analyst Brian Skorney weighed in on Gilead Sciences (NASDAQ: GILD) saying they are incrementally negative following 4Q14 earnings call.Skorney ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Gilead Sciences (GILD) Commentary Does Little to Quell Fears But Stock Undervalued - CowenFebruary 4, 2015 9:08 AM Gilead (GILD) Price Target Lowered to $118 at RBC Capital February 4, 2015 9:04 AM Gilead Sciences (GILD) PT Trimmed to $116 at Piper Jaffray as Guidance was a LetdownFebruary 4, 2015 8:54 AM Goldman Sachs Lowers Its Price Target on Gilead (GILD) to $85 February 4, 2015 8:26 AM Gilead Sciences (GILD) Estimates Trimmed at Needham & Company Post Q4; 'Buy' MaintainedFebruary 4, 2015 8:16 AM Gilead Sciences (GILD) PT Trimmed to $141 at Nomura Posts Q4February 4, 2015 7:40 AM Gilead Sciences (GILD) Approves Dividend Program; Adds $15B to Buyback AuthorizationFebruary 3, 2015 4:07 PM Gilead Sciences (GILD) Tops Q4 EPS by 22c; Approves Dividend Program, $15B BuybackFebruary 3, 2015 4:06 PM